Based on this result, in clinical practice, PUS1 detection is recommended for patients with chronic liver disease to be a biomarker or a supplementary detection for APF biomarker in early and definite diagnosis for the HCC patients who cannot be clearly identified by imaging examination. This evidence concerns the gene PUS1 and hepatocellular carcinoma.